# ELE-101 Safety & Tolerability Study in Healthy Participants and Patients With Depression

> **NCT05434156** · PHASE1,PHASE2 · ACTIVE_NOT_RECRUITING · sponsor: **Eleusis Therapeutics** · enrollment: 84 (estimated)

## Conditions studied

- Healthy Volunteers
- Major Depressive Disorder
- Depression

## Interventions

- **DRUG:** ELE-101
- **DRUG:** ELE-101 Placebo

## Key facts

- **NCT ID:** NCT05434156
- **Lead sponsor:** Eleusis Therapeutics
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** ACTIVE_NOT_RECRUITING
- **Start date:** 2022-10-27
- **Primary completion:** 2025-12
- **Final completion:** 2026-03
- **Target enrollment:** 84 (ESTIMATED)
- **Last updated:** 2025-02-19

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05434156

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05434156, "ELE-101 Safety & Tolerability Study in Healthy Participants and Patients With Depression". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT05434156. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*